Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01849848 | Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 17 | SymBio PharmaceuticalsINDUSTRY | 1 | Feb 6, 2015 | clinicaltrials |
| NCT00440583 | The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP | completed | Phase 2 | 15 | Mahidol UniversityOTHER | 1 | Jan 30, 2015 | clinicaltrials |
| NCT00908232 | Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD(SEQUENTIAL) | completed | Phase 2 | 163 | Janssen-Cilag International NVINDUSTRY | 10 | Jan 15, 2015 | clinicaltrials |
| NCT00435916 | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 46 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00193492 | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jan 5, 2015 | clinicaltrials |
| NCT00220285 | Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 45 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00079755 | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma | completed | Phase 2 | 80 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01998893 | A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma | completed | Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00833560 | A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy | completed | Phase 2 | 401 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT00911859 | A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients | completed | Phase 2 | 118 | Janssen Research & Development, LLCINDUSTRY | 11 | Nov 18, 2014 | clinicaltrials |
| NCT01470456 | Combination of SAR3419 and Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 50 | SanofiINDUSTRY | 3 | Nov 13, 2014 | clinicaltrials |
| NCT00891839 | Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma | completed | Phase 2 | 45 | CephalonINDUSTRY | 2 | Nov 4, 2014 | clinicaltrials |
| NCT00433537 | Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma | completed | Phase 2 | 77 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2014 | clinicaltrials |
| NCT00388193 | Rituximab Combined With Chemotherapy in Burkitt's Lymphoma | completed | Phase 2 | 20 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00564200 | MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning(MINIALO-VELCAD) | completed | Phase 2 | 30 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT00869999 | Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | completed | Phase 2 | 26 | Massachusetts General HospitalOTHER | 1 | Oct 27, 2014 | clinicaltrials |
| NCT01926639 | Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma(Lymvac-1) | completed | Phase 2 | 14 | Oslo University HospitalOTHER | 1 | Oct 23, 2014 | clinicaltrials |
| NCT00505895 | FM 140 vs FM100 Study in Patients With Multiple Myeloma | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2014 | clinicaltrials |
| NCT01502982 | Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)(CRY-04) | completed | Phase 2 | 160 | Nordic Lymphoma GroupNETWORK | 4 | Sep 30, 2014 | clinicaltrials |
| NCT01095757 | Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection | completed | Phase 2 | 45 | Emory UniversityOTHER | 1 | Sep 29, 2014 | clinicaltrials |
| NCT00057811 | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | completed | Phase 2 | 97 | Children's Oncology GroupNETWORK | 1 | Sep 19, 2014 | clinicaltrials |
| NCT01290120 | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma | completed | Phase 2 | 182 | Northern Italy Leukemia GroupOTHER | 1 | Sep 16, 2014 | clinicaltrials |
| NCT00225212 | Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Sep 15, 2014 | clinicaltrials |
| NCT00532259 | CT-011 MAb in DLBCL Patients Following ASCT | completed | Phase 2 | 72 | CureTech LtdINDUSTRY | 3 | Sep 12, 2014 | clinicaltrials |
| NCT01499303 | Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer | completed | Phase 2 | 101 | AstraZenecaINDUSTRY | 2 | Aug 22, 2014 | clinicaltrials |
| NCT00576758 | GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma | completed | Phase 2 | 175 | Hoffmann-La RocheINDUSTRY | 17 | Aug 19, 2014 | clinicaltrials |
| NCT00691704 | Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy | completed | Phase 2 | 18 | Cristina GasparettoOTHER | 1 | Aug 19, 2014 | clinicaltrials |
| NCT00972959 | Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy | completed | Phase 2 | 17 | University of AthensOTHER | 1 | Aug 5, 2014 | clinicaltrials |
| NCT00185965 | CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas | completed | Phase 1 / Phase 2 | 30 | Ronald LevyOTHER | 1 | Aug 1, 2014 | clinicaltrials |
| NCT00586755 | Intensive Induction Therapy Followed by High Dose Chemo and BM Transplant for Mantle Cell Lymphoma | completed | Phase 2 | 48 | Duke UniversityOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT00494780 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients(MUNIN) | completed | Phase 2 | 59 | GlaxoSmithKlineINDUSTRY | 1 | Jul 11, 2014 | clinicaltrials |
| NCT00586014 | High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma | completed | Phase 2 | 91 | Duke UniversityOTHER | 0 | Jul 8, 2014 | clinicaltrials |
| NCT00901147 | Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma | completed | Phase 2 | 25 | Singapore General HospitalOTHER | 3 | Jun 27, 2014 | clinicaltrials |
| NCT01096342 | Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 2 | Jun 18, 2014 | clinicaltrials |
| NCT01283776 | Cyclophosphamide as Sole Graft-Versus-Host-Prophylaxis After Allogeneic Stem Cell Transplantation(OCTET-CY) | completed | Phase 2 | 11 | University of CologneOTHER | 1 | Jun 10, 2014 | clinicaltrials |
| NCT00580034 | Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 176 | David Rizzieri, MDOTHER | 1 | Jun 3, 2014 | clinicaltrials |
| NCT00075881 | Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00142116 | Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 25 | Steven P. Treon, MD, PhDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00597714 | Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant | completed | Phase 2 | 264 | David Rizzieri, MDOTHER | 1 | Jun 2, 2014 | clinicaltrials |
| NCT00117988 | 17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00302757 | Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00306111 | Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma | completed | Phase 2 | 14 | University Hospital TuebingenOTHER | 1 | May 29, 2014 | clinicaltrials |
| NCT00054639 | Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00514137 | Sunitinib in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00058019 | Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | completed | Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00290472 | CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | completed | Phase 2 | 89 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT01280526 | A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas(Ro-CHOP) | completed | Phase 1 / Phase 2 | 37 | The Lymphoma Academic Research OrganisationOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00184080 | Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 7 | University of Southern CaliforniaOTHER | 1 | May 21, 2014 | clinicaltrials |
| NCT00872521 | A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma | completed | Phase 2 | 107 | Janssen-Cilag Pty LtdINDUSTRY | 1 | May 16, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Feb 16, 2015source: clinicaltrials